EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 9.97

Change

-0.92 (-8.45)%

Market Cap

N/A

Volume

1.47M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.08 (+1.77%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

+0.02 (+0.15%)

USD 45.03B
HLN Haleon plc

-0.05 (-0.54%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.21 (-1.42%)

USD 12.67B
CTLT Catalent Inc

-0.10 (-0.17%)

USD 10.78B
ELAN Elanco Animal Health

+0.07 (+0.50%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.35 (-3.83%)

USD 3.37B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.22 (-2.38%)

USD 2.80B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

-0.05 (-9.04%)

USD 1.73M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

-0.65 (-0.80%)

USD 0.04B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

-0.56 (-0.80%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 19.51 % 0.00 %

-0.41 (-0.80%)

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.06 % 0.00 %

-0.09 (-0.80%)

CAD 3.94M
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

+0.08 (+-0.80%)

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

N/A

USD 0.13B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

-2.35 (-0.80%)

N/A
FEUZ:LSE First Trust Eurozone Alph.. 1.21 % 0.00 %

-17.50 (-0.80%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.21 % 0.00 %

-25.00 (-0.80%)

USD 0.02B
LDEU:LSE L&G Quality Equity Divide.. 1.13 % 0.00 %

-0.02 (-0.80%)

USD 0.04B
EUMD:LSE iShares MSCI Europe Mid C.. 1.04 % 0.00 %

-0.01 (-0.80%)

USD 0.26B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.96 % 0.00 %

+0.03 (+-0.80%)

USD 0.02B
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

-0.43 (-0.80%)

USD 2.56B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 315.42% 87% B+ 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 315.42% 87% B+ 99% N/A
Trailing 12 Months  
Capital Gain 351.13% 87% B+ 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 351.13% 87% B+ 99% N/A
Trailing 5 Years  
Capital Gain -81.81% 14% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.81% 14% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -29.19% 7% C- 1% F
Dividend Return -29.19% 7% C- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.53% 27% F 12% F
Risk Adjusted Return -39.17% 20% F 7% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector